No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > NKG2D


Brief Information

Name:NKG2-D type II integral membrane protein
Target Synonym:Killer cell lectin-like receptor subfamily K member 1,NK cell receptor D,NKG2-D-activating NK receptor,CD314,D12S2489E,KLR,DNA Segment On Chromosome 12 (Unique) 2489 Expressed Sequence,Killer Cell Lectin Like Receptor K1,NKG2-D,Killer Cell Lectin-Like Receptor Subfamily K, Member 1,KLRK1,CD314 Antigen
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Cynomolgus NKG2D, His Tag (Cat. No. NKD-C5248) at 5 μg/mL (100 μL/well) can bind Human MICA, Fc Tag (Cat. No. MIA-H5253) with a linear range of 0.2-2 ng/mL (QC tested).

NKG2D MALS images

The purity of Biotinylated Human NKG2D Protein, Avitag,His Tag (Cat. No. NKD-H82Q3) is more than 85% and the molecular weight of this protein is around 36-46 kDa verified by SEC-MALS.

Synonym Name

NKG2D,CD314,KLRK1,NK cell receptor D


NKG2D is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors, also known as KLRK1, CD314, D12S2489E, KLR and killer cell lectin like receptor K1. NKG2D itself forms a homodimer whose ectodomains serve for ligand binding. NKG2D is a major recognition receptor for the detection and elimination of transformed and infected cells as its ligands are induced during cellular stress, either as a result of infection or genomic stress such as in cancer. In NK cells, NKG2D serves as an activating receptor, which itself is able to trigger cytotoxicity. The function of NKG2D on CD8+ T cells is to send co-stimulatory signals to activate them.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tesnatilimab IPH-2301; IPH-23XX; JNJ-4500; JNJ-64304500; NNC-0142-002; NNC-0142-0002; NNC-0142-0000-0002; NN-8555 Phase 2 Clinical Innate Pharma Alopecia Areata; Arthritis, Rheumatoid; Celiac Disease; Inflammation; Crohn Disease Details
NKG2D-ACE2 CAR-NK cell therapy (Sidemu Biotechnology Technology) Phase 2 Clinical Chongqing Sidemu Biotechnology Technology Co Ltd Coronavirus Disease 2019 (COVID-19) Details
QEQ-278 QEQ-278 Phase 1 Clinical Novartis Pharmaceuticals Corp Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung Details
NKG2D CAR-T Cell therapy (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Colorectal Neoplasms; Leukemia, Myeloid, Acute Details
NKG2D CAR-T cell therapy (Uwell Biopharma) UWN2D Clinical Uwell Biopharma Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Correo electrónico
+1 888-377-6111
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje